Natera, Inc. NASDAQ:NTRA

Founder-led company

Natera stock price today

$160.06
-0.19
-0.12%
Financial Health
0
1
2
3
4
5
6
7
8
9

Natera stock price monthly change

+43.60%
month

Natera stock price quarterly change

+43.60%
quarter

Natera stock price yearly change

+161.78%
year

Natera key metrics

Market Cap
20.84B
Enterprise value
5.08B
P/E
-9.75
EV/Sales
6.20
EV/EBITDA
-9.85
Price/Sales
6.23
Price/Book
7.24
PEG ratio
1.41
EPS
-3.13
Revenue
1.20B
EBITDA
-351.25M
Income
-365.46M
Revenue Q/Q
52.11%
Revenue Y/Y
39.25%
Profit margin
-66.79%
Oper. margin
-65.96%
Gross margin
44.69%
EBIT margin
-65.96%
EBITDA margin
-29.06%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Natera stock price history

Natera stock forecast

Natera financial statements

Average Price Target
Last Year

$148.43

Potential downside: -7.26%

Based on estimate of 5 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Natera, Inc. (NASDAQ:NTRA): Profit margin
Jun 2023 261.40M -110.80M -42.39%
Sep 2023 268.30M -109.03M -40.64%
Dec 2023 311.10M -78.03M -25.08%
Mar 2024 367.74M -67.59M -18.38%
Natera, Inc. (NASDAQ:NTRA): Debt to assets
Jun 2023 1247893000 651.74M 52.23%
Sep 2023 1446520000 661.86M 45.76%
Dec 2023 1457125000 691.79M 47.48%
Mar 2024 1468205000 674.09M 45.91%
Natera, Inc. (NASDAQ:NTRA): Cash Flow
Jun 2023 -78.38M 47.03M 9.31M
Sep 2023 -29.55M 81.14M 236.00M
Dec 2023 -58.12M 24.66M 6.84M
Mar 2024 27.00M 138.25M 6.46M

Natera alternative data

Natera, Inc. (NASDAQ:NTRA): Employee count
Aug 2023 2,958
Sep 2023 2,958
Oct 2023 2,958
Nov 2023 2,958
Dec 2023 2,958
Jan 2024 2,958
Feb 2024 2,958
Mar 2024 2,958
Apr 2024 2,958
May 2024 2,958
Jun 2024 3,282
Jul 2024 3,282

Natera other data

43.07% -56.93%
of NTRA is owned by hedge funds
42.38M -65.52M
shares is hold by hedge funds

Natera, Inc. (NASDAQ:NTRA): Insider trades (number of shares)
Period Buy Sel
Mar 2024 0 57347
Apr 2024 0 132206
May 2024 0 41345
Oct 2024 0 24071
Nov 2024 0 99852
Dec 2024 0 262895
Transaction Date Insider Security Shares Price per share Total value Source
Sale
FESKO JOHN officer: PRESIDENT, CHIEF BUS. ..
Common Stock 1 $157.95 $158
Sale
FESKO JOHN officer: PRESIDENT, CHIEF BUS. ..
Common Stock 668 $159.6 $106,615
Sale
MOSHKEVICH SOLOMON officer: PRESIDENT, CLINICALDIA..
Common Stock 2 $158.06 $316
Sale
MOSHKEVICH SOLOMON officer: PRESIDENT, CLINICALDIA..
Common Stock 3 $158.19 $475
Sale
MOSHKEVICH SOLOMON officer: PRESIDENT, CLINICALDIA..
Common Stock 2,423 $159.6 $386,720
Sale
SHEENA JONATHAN director, other: .. Common Stock 338 $165.98 $56,100
Sale
SHEENA JONATHAN director, other: .. Common Stock 1,825 $167.25 $305,231
Sale
SHEENA JONATHAN director, other: .. Common Stock 537 $168.15 $90,294
Sale
SHEENA JONATHAN director, other: .. Common Stock 152 $166.01 $25,233
Sale
SHEENA JONATHAN director, other: .. Common Stock 238 $166.18 $39,550
Patent
Grant
Filling date: 5 Oct 2021 Issue date: 20 Sep 2022
Grant
Filling date: 21 Jun 2018 Issue date: 20 Sep 2022
Grant
Filling date: 10 May 2016 Issue date: 20 Sep 2022
Application
Filling date: 6 May 2022 Issue date: 8 Sep 2022
Grant
Filling date: 20 Mar 2019 Issue date: 16 Aug 2022
Application
Filling date: 29 May 2020 Issue date: 11 Aug 2022
Grant
Filling date: 28 Feb 2019 Issue date: 9 Aug 2022
Grant
Filling date: 19 Jun 2018 Issue date: 9 Aug 2022
Grant
Filling date: 24 Jan 2020 Issue date: 19 Jul 2022
Application
Filling date: 11 Mar 2022 Issue date: 7 Jul 2022
Insider Compensation
Mr. Steve Leonard Chapman (1979) Chief Executive Officer, Pres & Director
$792,170
Mr. Robert A. Schueren (1962) Chief Operating Officer $691,170
Mr. Michael Brophy (1980) Chief Financial Officer $631,730
Dr. Matthew Rabinowitz Ph.D. (1973) Co-Founder & Executive Chairman $514,260
Mr. Jonathan Sheena (1973) Co-Founder & Director $293,910
Saturday, 21 December 2024
fool.com
Tuesday, 17 December 2024
zacks.com
businesswire.com
Monday, 2 December 2024
businesswire.com
Wednesday, 27 November 2024
businesswire.com
Monday, 25 November 2024
businesswire.com
prnewswire.com
businesswire.com
Thursday, 21 November 2024
businesswire.com
fool.com
Tuesday, 12 November 2024
seekingalpha.com
zacks.com
zacks.com
Monday, 11 November 2024
marketbeat.com
Friday, 8 November 2024
businesswire.com
Friday, 1 November 2024
businesswire.com
Thursday, 31 October 2024
seekingalpha.com
forbes.com
Wednesday, 23 October 2024
zacks.com
zacks.com
Monday, 23 September 2024
businesswire.com
Monday, 16 September 2024
businesswire.com
Saturday, 14 September 2024
businesswire.com
Sunday, 8 September 2024
businesswire.com
Wednesday, 28 August 2024
businesswire.com
Tuesday, 20 August 2024
fool.com
Wednesday, 14 August 2024
seekingalpha.com
Thursday, 8 August 2024
zacks.com
zacks.com
Tuesday, 6 August 2024
businesswire.com
  • What's the price of Natera stock today?

    One share of Natera stock can currently be purchased for approximately $160.06.

  • When is Natera's next earnings date?

    Unfortunately, Natera's (NTRA) next earnings date is currently unknown.

  • Does Natera pay dividends?

    No, Natera does not pay dividends.

  • How much money does Natera make?

    Natera has a market capitalization of 20.84B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 31.99% to 1.08B US dollars.

  • What is Natera's stock symbol?

    Natera, Inc. is traded on the NASDAQ under the ticker symbol "NTRA".

  • What is Natera's primary industry?

    Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.

  • How do i buy shares of Natera?

    Shares of Natera can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Natera's key executives?

    Natera's management team includes the following people:

    • Mr. Steve Leonard Chapman Chief Executive Officer, Pres & Director(age: 46, pay: $792,170)
    • Mr. Robert A. Schueren Chief Operating Officer(age: 63, pay: $691,170)
    • Mr. Michael Brophy Chief Financial Officer(age: 45, pay: $631,730)
    • Dr. Matthew Rabinowitz Ph.D. Co-Founder & Executive Chairman(age: 52, pay: $514,260)
    • Mr. Jonathan Sheena Co-Founder & Director(age: 52, pay: $293,910)
  • Is Natera founder-led company?

    Yes, Natera is a company led by its founders Dr. Matthew Rabinowitz Ph.D. and Mr. Jonathan Sheena.

  • How many employees does Natera have?

    As Jul 2024, Natera employs 3,282 workers, which is 11% more then previous quarter.

  • When Natera went public?

    Natera, Inc. is publicly traded company for more then 10 years since IPO on 1 Jul 2015.

  • What is Natera's official website?

    The official website for Natera is natera.com.

  • Where are Natera's headquarters?

    Natera is headquartered at 13011 McCallen Pass Building A, San Carlos, CA.

  • How can i contact Natera?

    Natera's mailing address is 13011 McCallen Pass Building A, San Carlos, CA and company can be reached via phone at +65 02499090.

  • What is Natera stock forecast & price target?

    Based on 5 Wall Street analysts` predicted price targets for Natera in the last 12 months, the avarage price target is $148.43. The average price target represents a -7.26% change from the last price of $160.06.

Natera company profile:

Natera, Inc.

natera.com
Exchange:

NASDAQ

Full time employees:

3,282

Industry:

Medical - Diagnostics & Research

Sector:

Healthcare

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

13011 McCallen Pass Building A
San Carlos, CA 78753

CIK: 0001604821
ISIN: US6323071042
CUSIP: 632307104